Koninklijke Philips N.V.
Koninklijke Philips N.V. PHG Peers
See (PHG) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHG | $22.80 | -0.04% | 21.1B | 78.62 | $0.29 | +3.88% |
| ABT | $133.70 | +0.10% | 232.6B | 17.39 | $7.69 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $103.09 | -1.04% | 152.5B | 75.25 | $1.37 | N/A |
| SYK | $380.93 | +0.02% | 145.6B | 51.62 | $7.38 | +0.86% |
| MDT | $85.53 | +2.14% | 109.7B | 23.69 | $3.61 | +3.28% |
| EW | $77.72 | -0.48% | 45.6B | 32.12 | $2.42 | N/A |
| DXCM | $86.77 | +1.47% | 34B | 65.24 | $1.33 | N/A |
| STE | $243.27 | +0.49% | 23.9B | 39.56 | $6.15 | +0.92% |
| PODD | $323.20 | -0.55% | 22.7B | 58.13 | $5.56 | N/A |
Stock Comparison
PHG vs ABT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ABT has a market cap of 232.6B. Regarding current trading prices, PHG is priced at $22.80, while ABT trades at $133.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ABT's P/E ratio is 17.39. In terms of profitability, PHG's ROE is +0.03%, compared to ABT's ROE of +0.31%. Regarding short-term risk, PHG is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs BSX-PA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PHG is priced at $22.80, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PHG's ROE is +0.03%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BSX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BSX has a market cap of 152.5B. Regarding current trading prices, PHG is priced at $22.80, while BSX trades at $103.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BSX's P/E ratio is 75.25. In terms of profitability, PHG's ROE is +0.03%, compared to BSX's ROE of +0.10%. Regarding short-term risk, PHG is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SYK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SYK has a market cap of 145.6B. Regarding current trading prices, PHG is priced at $22.80, while SYK trades at $380.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SYK's P/E ratio is 51.62. In terms of profitability, PHG's ROE is +0.03%, compared to SYK's ROE of +0.11%. Regarding short-term risk, PHG is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs MDT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, MDT has a market cap of 109.7B. Regarding current trading prices, PHG is priced at $22.80, while MDT trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas MDT's P/E ratio is 23.69. In terms of profitability, PHG's ROE is +0.03%, compared to MDT's ROE of +0.09%. Regarding short-term risk, PHG is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs EW Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, EW has a market cap of 45.6B. Regarding current trading prices, PHG is priced at $22.80, while EW trades at $77.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas EW's P/E ratio is 32.12. In terms of profitability, PHG's ROE is +0.03%, compared to EW's ROE of +0.49%. Regarding short-term risk, PHG is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs DXCM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, DXCM has a market cap of 34B. Regarding current trading prices, PHG is priced at $22.80, while DXCM trades at $86.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas DXCM's P/E ratio is 65.24. In terms of profitability, PHG's ROE is +0.03%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, PHG is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs STE Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, STE has a market cap of 23.9B. Regarding current trading prices, PHG is priced at $22.80, while STE trades at $243.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas STE's P/E ratio is 39.56. In terms of profitability, PHG's ROE is +0.03%, compared to STE's ROE of +0.09%. Regarding short-term risk, PHG is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PODD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, PODD has a market cap of 22.7B. Regarding current trading prices, PHG is priced at $22.80, while PODD trades at $323.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas PODD's P/E ratio is 58.13. In terms of profitability, PHG's ROE is +0.03%, compared to PODD's ROE of +0.35%. Regarding short-term risk, PHG is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs ZBH Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ZBH has a market cap of 18.2B. Regarding current trading prices, PHG is priced at $22.80, while ZBH trades at $91.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ZBH's P/E ratio is 20.42. In terms of profitability, PHG's ROE is +0.03%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, PHG is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ABMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PHG is priced at $22.80, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PHG's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PHG is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs ALGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ALGN has a market cap of 13B. Regarding current trading prices, PHG is priced at $22.80, while ALGN trades at $179.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ALGN's P/E ratio is 32.58. In terms of profitability, PHG's ROE is +0.03%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PHG is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SNN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, PHG is priced at $22.80, while SNN trades at $29.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SNN's P/E ratio is 30.98. In terms of profitability, PHG's ROE is +0.03%, compared to SNN's ROE of +0.08%. Regarding short-term risk, PHG is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SWAV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PHG is priced at $22.80, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PHG's ROE is +0.03%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, PHG is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PEN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, PEN has a market cap of 10B. Regarding current trading prices, PHG is priced at $22.80, while PEN trades at $257.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas PEN's P/E ratio is 240.41. In terms of profitability, PHG's ROE is +0.03%, compared to PEN's ROE of +0.04%. Regarding short-term risk, PHG is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs GMED Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, GMED has a market cap of 8.1B. Regarding current trading prices, PHG is priced at $22.80, while GMED trades at $59.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas GMED's P/E ratio is 44.56. In terms of profitability, PHG's ROE is +0.03%, compared to GMED's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BIO-B Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, PHG is priced at $22.80, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, PHG's ROE is +0.03%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, PHG is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs BIO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BIO has a market cap of 6B. Regarding current trading prices, PHG is priced at $22.80, while BIO trades at $220.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BIO's P/E ratio is -2.88. In terms of profitability, PHG's ROE is +0.03%, compared to BIO's ROE of -0.32%. Regarding short-term risk, PHG is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BRKR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BRKR has a market cap of 5.7B. Regarding current trading prices, PHG is priced at $22.80, while BRKR trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BRKR's P/E ratio is 71.92. In terms of profitability, PHG's ROE is +0.03%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, PHG is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs GKOS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, PHG is priced at $22.80, while GKOS trades at $94.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas GKOS's P/E ratio is -41.61. In terms of profitability, PHG's ROE is +0.03%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NARI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PHG is priced at $22.80, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas NARI's P/E ratio is -59.24. In terms of profitability, PHG's ROE is +0.03%, compared to NARI's ROE of -0.18%. Regarding short-term risk, PHG is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs IRTC Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, IRTC has a market cap of 4.6B. Regarding current trading prices, PHG is priced at $22.80, while IRTC trades at $145.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas IRTC's P/E ratio is -46.34. In terms of profitability, PHG's ROE is +0.03%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, PHG is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TMDX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, PHG is priced at $22.80, while TMDX trades at $128.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas TMDX's P/E ratio is 90.66. In terms of profitability, PHG's ROE is +0.03%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, PHG is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ITGR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, PHG is priced at $22.80, while ITGR trades at $119.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ITGR's P/E ratio is 55.79. In terms of profitability, PHG's ROE is +0.03%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs INSP Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, INSP has a market cap of 4.1B. Regarding current trading prices, PHG is priced at $22.80, while INSP trades at $138.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas INSP's P/E ratio is 63.22. In terms of profitability, PHG's ROE is +0.03%, compared to INSP's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AXNX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PHG is priced at $22.80, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PHG's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PHG is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs PRCT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, PRCT has a market cap of 3.3B. Regarding current trading prices, PHG is priced at $22.80, while PRCT trades at $59.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas PRCT's P/E ratio is -35.49. In terms of profitability, PHG's ROE is +0.03%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, PHG is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LIVN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, PHG is priced at $22.80, while LIVN trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas LIVN's P/E ratio is -10.84. In terms of profitability, PHG's ROE is +0.03%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, PHG is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NUVA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PHG is priced at $22.80, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PHG's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PHG is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ATEC Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ATEC has a market cap of 1.8B. Regarding current trading prices, PHG is priced at $22.80, while ATEC trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ATEC's P/E ratio is -11.10. In terms of profitability, PHG's ROE is +0.03%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, PHG is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs UFPT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, PHG is priced at $22.80, while UFPT trades at $238.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas UFPT's P/E ratio is 29.31. In terms of profitability, PHG's ROE is +0.03%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, PHG is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CNMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CNMD has a market cap of 1.8B. Regarding current trading prices, PHG is priced at $22.80, while CNMD trades at $56.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CNMD's P/E ratio is 14.94. In terms of profitability, PHG's ROE is +0.03%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, PHG is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TNDM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, PHG is priced at $22.80, while TNDM trades at $20.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas TNDM's P/E ratio is -7.39. In terms of profitability, PHG's ROE is +0.03%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, PHG is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs HSKA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PHG is priced at $22.80, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PHG's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PHG is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs AORT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $22.80, while AORT trades at $28.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AORT's P/E ratio is -55.80. In terms of profitability, PHG's ROE is +0.03%, compared to AORT's ROE of -0.07%. Regarding short-term risk, PHG is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs AHCO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, PHG is priced at $22.80, while AHCO trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AHCO's P/E ratio is 15.28. In terms of profitability, PHG's ROE is +0.03%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, PHG is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SILK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $22.80, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SILK's P/E ratio is -18.96. In terms of profitability, PHG's ROE is +0.03%, compared to SILK's ROE of -0.29%. Regarding short-term risk, PHG is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SSII Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $22.80, while SSII trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SSII's P/E ratio is -71.37. In terms of profitability, PHG's ROE is +0.03%, compared to SSII's ROE of -1.33%. Regarding short-term risk, PHG is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs FNA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $22.80, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas FNA's P/E ratio is -19.83. In terms of profitability, PHG's ROE is +0.03%, compared to FNA's ROE of -0.36%. Regarding short-term risk, PHG is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs ESTA Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ESTA has a market cap of 1.1B. Regarding current trading prices, PHG is priced at $22.80, while ESTA trades at $36.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ESTA's P/E ratio is -11.75. In terms of profitability, PHG's ROE is +0.03%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, PHG is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs INMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, INMD has a market cap of 1B. Regarding current trading prices, PHG is priced at $22.80, while INMD trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas INMD's P/E ratio is 6.59. In terms of profitability, PHG's ROE is +0.03%, compared to INMD's ROE of +0.25%. Regarding short-term risk, PHG is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs IART Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, IART has a market cap of 1B. Regarding current trading prices, PHG is priced at $22.80, while IART trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas IART's P/E ratio is -34.30. In terms of profitability, PHG's ROE is +0.03%, compared to IART's ROE of -0.03%. Regarding short-term risk, PHG is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CSII Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PHG is priced at $22.80, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CSII's P/E ratio is -20.83. In terms of profitability, PHG's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PHG is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SIBN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SIBN has a market cap of 805.4M. Regarding current trading prices, PHG is priced at $22.80, while SIBN trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SIBN's P/E ratio is -30.00. In terms of profitability, PHG's ROE is +0.03%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, PHG is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs IRMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, IRMD has a market cap of 760.1M. Regarding current trading prices, PHG is priced at $22.80, while IRMD trades at $59.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas IRMD's P/E ratio is 38.57. In terms of profitability, PHG's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PHG is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CRY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, PHG is priced at $22.80, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CRY's P/E ratio is 425.71. In terms of profitability, PHG's ROE is +0.03%, compared to CRY's ROE of -0.07%. Regarding short-term risk, PHG is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RXST Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, RXST has a market cap of 642.5M. Regarding current trading prices, PHG is priced at $22.80, while RXST trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas RXST's P/E ratio is -23.95. In terms of profitability, PHG's ROE is +0.03%, compared to RXST's ROE of -0.10%. Regarding short-term risk, PHG is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CBLL Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CBLL has a market cap of 612.4M. Regarding current trading prices, PHG is priced at $22.80, while CBLL trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CBLL's P/E ratio is -13.56. In terms of profitability, PHG's ROE is +0.03%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, PHG is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs BFLY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BFLY has a market cap of 582.4M. Regarding current trading prices, PHG is priced at $22.80, while BFLY trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BFLY's P/E ratio is -7.85. In terms of profitability, PHG's ROE is +0.03%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs APEN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PHG is priced at $22.80, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas APEN's P/E ratio is -9.43. In terms of profitability, PHG's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PHG is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs AVNS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AVNS has a market cap of 574.8M. Regarding current trading prices, PHG is priced at $22.80, while AVNS trades at $12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AVNS's P/E ratio is -1.50. In terms of profitability, PHG's ROE is +0.03%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, PHG is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BFLY-WT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BFLY-WT has a market cap of 571.2M. Regarding current trading prices, PHG is priced at $22.80, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs AXGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AXGN has a market cap of 516.5M. Regarding current trading prices, PHG is priced at $22.80, while AXGN trades at $11.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AXGN's P/E ratio is -70.87. In terms of profitability, PHG's ROE is +0.03%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, PHG is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs KIDS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, KIDS has a market cap of 506.5M. Regarding current trading prices, PHG is priced at $22.80, while KIDS trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas KIDS's P/E ratio is -11.62. In terms of profitability, PHG's ROE is +0.03%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, PHG is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NPCE Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, NPCE has a market cap of 444.7M. Regarding current trading prices, PHG is priced at $22.80, while NPCE trades at $13.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas NPCE's P/E ratio is -16.54. In terms of profitability, PHG's ROE is +0.03%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, PHG is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BVS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BVS has a market cap of 441.9M. Regarding current trading prices, PHG is priced at $22.80, while BVS trades at $6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BVS's P/E ratio is -13.87. In terms of profitability, PHG's ROE is +0.03%, compared to BVS's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OFIX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, OFIX has a market cap of 432.6M. Regarding current trading prices, PHG is priced at $22.80, while OFIX trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas OFIX's P/E ratio is -2.98. In terms of profitability, PHG's ROE is +0.03%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, PHG is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SRDX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SRDX has a market cap of 421.8M. Regarding current trading prices, PHG is priced at $22.80, while SRDX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SRDX's P/E ratio is -21.07. In terms of profitability, PHG's ROE is +0.03%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, PHG is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs SENS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SENS has a market cap of 402.2M. Regarding current trading prices, PHG is priced at $22.80, while SENS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SENS's P/E ratio is -4.85. In terms of profitability, PHG's ROE is +0.03%, compared to SENS's ROE of -7.46%. Regarding short-term risk, PHG is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SMLR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SMLR has a market cap of 396.4M. Regarding current trading prices, PHG is priced at $22.80, while SMLR trades at $35.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SMLR's P/E ratio is -14.87. In terms of profitability, PHG's ROE is +0.03%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, PHG is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TMCI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, TMCI has a market cap of 364.8M. Regarding current trading prices, PHG is priced at $22.80, while TMCI trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas TMCI's P/E ratio is -6.82. In terms of profitability, PHG's ROE is +0.03%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, PHG is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CTKB Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CTKB has a market cap of 361.6M. Regarding current trading prices, PHG is priced at $22.80, while CTKB trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CTKB's P/E ratio is -31.72. In terms of profitability, PHG's ROE is +0.03%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, PHG is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CLPT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CLPT has a market cap of 358.4M. Regarding current trading prices, PHG is priced at $22.80, while CLPT trades at $12.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CLPT's P/E ratio is -16.68. In terms of profitability, PHG's ROE is +0.03%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, PHG is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, OM has a market cap of 344M. Regarding current trading prices, PHG is priced at $22.80, while OM trades at $19.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas OM's P/E ratio is -0.67. In terms of profitability, PHG's ROE is +0.03%, compared to OM's ROE of -1.45%. Regarding short-term risk, PHG is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NNOX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, NNOX has a market cap of 338.6M. Regarding current trading prices, PHG is priced at $22.80, while NNOX trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas NNOX's P/E ratio is -5.84. In terms of profitability, PHG's ROE is +0.03%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, PHG is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs VREX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, VREX has a market cap of 328.3M. Regarding current trading prices, PHG is priced at $22.80, while VREX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas VREX's P/E ratio is -7.68. In terms of profitability, PHG's ROE is +0.03%, compared to VREX's ROE of -0.08%. Regarding short-term risk, PHG is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs PACB Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, PACB has a market cap of 315.1M. Regarding current trading prices, PHG is priced at $22.80, while PACB trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas PACB's P/E ratio is -0.38. In terms of profitability, PHG's ROE is +0.03%, compared to PACB's ROE of -1.70%. Regarding short-term risk, PHG is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CERS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CERS has a market cap of 276.2M. Regarding current trading prices, PHG is priced at $22.80, while CERS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CERS's P/E ratio is -14.45. In terms of profitability, PHG's ROE is +0.03%, compared to CERS's ROE of -0.35%. Regarding short-term risk, PHG is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs VMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, VMD has a market cap of 268.4M. Regarding current trading prices, PHG is priced at $22.80, while VMD trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas VMD's P/E ratio is 22.63. In terms of profitability, PHG's ROE is +0.03%, compared to VMD's ROE of +0.10%. Regarding short-term risk, PHG is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ZIMV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ZIMV has a market cap of 259.1M. Regarding current trading prices, PHG is priced at $22.80, while ZIMV trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ZIMV's P/E ratio is -10.31. In terms of profitability, PHG's ROE is +0.03%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, PHG is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MXCT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, MXCT has a market cap of 242.4M. Regarding current trading prices, PHG is priced at $22.80, while MXCT trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas MXCT's P/E ratio is -5.70. In terms of profitability, PHG's ROE is +0.03%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, PHG is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SNWV Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SNWV has a market cap of 242.3M. Regarding current trading prices, PHG is priced at $22.80, while SNWV trades at $28.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SNWV's P/E ratio is -4.55. In terms of profitability, PHG's ROE is +0.03%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, PHG is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TCMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, TCMD has a market cap of 238.5M. Regarding current trading prices, PHG is priced at $22.80, while TCMD trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas TCMD's P/E ratio is 15.55. In terms of profitability, PHG's ROE is +0.03%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, PHG is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MASS Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, MASS has a market cap of 237M. Regarding current trading prices, PHG is priced at $22.80, while MASS trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas MASS's P/E ratio is -2.98. In terms of profitability, PHG's ROE is +0.03%, compared to MASS's ROE of -0.13%. Regarding short-term risk, PHG is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CATX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CATX has a market cap of 231.6M. Regarding current trading prices, PHG is priced at $22.80, while CATX trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CATX's P/E ratio is -2.54. In terms of profitability, PHG's ROE is +0.03%, compared to CATX's ROE of -0.27%. Regarding short-term risk, PHG is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs NVRO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PHG is priced at $22.80, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PHG's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PHG is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs QTRX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, QTRX has a market cap of 210.6M. Regarding current trading prices, PHG is priced at $22.80, while QTRX trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas QTRX's P/E ratio is -4.37. In terms of profitability, PHG's ROE is +0.03%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs EYES Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, PHG is priced at $22.80, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas EYES's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to EYES's ROE of -0.26%. Regarding short-term risk, PHG is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs SGHT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, SGHT has a market cap of 207.8M. Regarding current trading prices, PHG is priced at $22.80, while SGHT trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas SGHT's P/E ratio is -4.10. In terms of profitability, PHG's ROE is +0.03%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, PHG is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs TLSI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, TLSI has a market cap of 196.4M. Regarding current trading prices, PHG is priced at $22.80, while TLSI trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas TLSI's P/E ratio is -4.72. In terms of profitability, PHG's ROE is +0.03%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, PHG is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BWAY Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BWAY has a market cap of 193.4M. Regarding current trading prices, PHG is priced at $22.80, while BWAY trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BWAY's P/E ratio is 46.55. In terms of profitability, PHG's ROE is +0.03%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, PHG is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs CVRX Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, CVRX has a market cap of 176.5M. Regarding current trading prices, PHG is priced at $22.80, while CVRX trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas CVRX's P/E ratio is -3.16. In terms of profitability, PHG's ROE is +0.03%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, PHG is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BSGM Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BSGM has a market cap of 176.1M. Regarding current trading prices, PHG is priced at $22.80, while BSGM trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BSGM's P/E ratio is -12.17. In terms of profitability, PHG's ROE is +0.03%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, PHG is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ELMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ELMD has a market cap of 172.6M. Regarding current trading prices, PHG is priced at $22.80, while ELMD trades at $20.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ELMD's P/E ratio is 26.05. In terms of profitability, PHG's ROE is +0.03%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, PHG is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs INGN Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, INGN has a market cap of 172.3M. Regarding current trading prices, PHG is priced at $22.80, while INGN trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas INGN's P/E ratio is -5.57. In terms of profitability, PHG's ROE is +0.03%, compared to INGN's ROE of -0.15%. Regarding short-term risk, PHG is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ANIK Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ANIK has a market cap of 166.2M. Regarding current trading prices, PHG is priced at $22.80, while ANIK trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ANIK's P/E ratio is -15.45. In terms of profitability, PHG's ROE is +0.03%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, PHG is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs PROF Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, PROF has a market cap of 164.7M. Regarding current trading prices, PHG is priced at $22.80, while PROF trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas PROF's P/E ratio is -4.53. In terms of profitability, PHG's ROE is +0.03%, compared to PROF's ROE of -0.70%. Regarding short-term risk, PHG is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RPID Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, RPID has a market cap of 163.5M. Regarding current trading prices, PHG is priced at $22.80, while RPID trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas RPID's P/E ratio is -3.62. In terms of profitability, PHG's ROE is +0.03%, compared to RPID's ROE of -0.56%. Regarding short-term risk, PHG is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LNSR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, LNSR has a market cap of 161.1M. Regarding current trading prices, PHG is priced at $22.80, while LNSR trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas LNSR's P/E ratio is -2.78. In terms of profitability, PHG's ROE is +0.03%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, PHG is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for PHG.
PHG vs AVR Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, AVR has a market cap of 160.7M. Regarding current trading prices, PHG is priced at $22.80, while AVR trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas AVR's P/E ratio is -2.53. In terms of profitability, PHG's ROE is +0.03%, compared to AVR's ROE of -2.92%. Regarding short-term risk, PHG is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs RCEL Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, RCEL has a market cap of 154.9M. Regarding current trading prices, PHG is priced at $22.80, while RCEL trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas RCEL's P/E ratio is -2.68. In terms of profitability, PHG's ROE is +0.03%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, PHG is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs BDMD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, BDMD has a market cap of 154M. Regarding current trading prices, PHG is priced at $22.80, while BDMD trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas BDMD's P/E ratio is 8.80. In terms of profitability, PHG's ROE is +0.03%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, PHG is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LUCD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, LUCD has a market cap of 128M. Regarding current trading prices, PHG is priced at $22.80, while LUCD trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas LUCD's P/E ratio is -1.08. In terms of profitability, PHG's ROE is +0.03%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, PHG is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs LUNG Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, LUNG has a market cap of 127.8M. Regarding current trading prices, PHG is priced at $22.80, while LUNG trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas LUNG's P/E ratio is -2.20. In terms of profitability, PHG's ROE is +0.03%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, PHG is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs ICAD Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, ICAD has a market cap of 107.1M. Regarding current trading prices, PHG is priced at $22.80, while ICAD trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas ICAD's P/E ratio is -20.53. In terms of profitability, PHG's ROE is +0.03%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, PHG is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs MYO Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, MYO has a market cap of 103.6M. Regarding current trading prices, PHG is priced at $22.80, while MYO trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas MYO's P/E ratio is -20.57. In terms of profitability, PHG's ROE is +0.03%, compared to MYO's ROE of -0.36%. Regarding short-term risk, PHG is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs OWLT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, OWLT has a market cap of 98.4M. Regarding current trading prices, PHG is priced at $22.80, while OWLT trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas OWLT's P/E ratio is -3.70. In terms of profitability, PHG's ROE is +0.03%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, PHG is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs HJLI Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PHG is priced at $22.80, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas HJLI's P/E ratio is N/A. In terms of profitability, PHG's ROE is +0.03%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, PHG is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.
PHG vs XTNT Comparison
PHG plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHG stands at 21.1B. In comparison, XTNT has a market cap of 95.8M. Regarding current trading prices, PHG is priced at $22.80, while XTNT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHG currently has a P/E ratio of 78.62, whereas XTNT's P/E ratio is -7.64. In terms of profitability, PHG's ROE is +0.03%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, PHG is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for PHG.